Fund

Kunlun Capital

昆仑资本

elsewhere's corpus doesn't carry a profile of Kunlun Capital itself — no founding date, fund size, or strategy description. It shows up only through its deals: most recently as the sole investor in Rongsutech's nearly RMB 100 million Series A+ (August 2026), a metal wire-feed additive manufacturing equipment maker , and earlier as a co-investor in allosteric drug discovery company Nutshell Therapeutics' 2021 Series A alongside Matrix Partners China and Source Code Capital, continuing to add in its 2022 $40 million A+ . Those bets suggest an interest in hard-tech and biotech, but that's as much as the material here supports.

AI-generated — may contain errors, please verify.

Kunlun CapitalFund
昆仑资本
渲染中…
Mentioned in 8 articles

Coverage